Replies to post #92769 on Biotech Values

[DewDiligence]

OSIP:

Any thoughts on other aspects of the situation?

I predict that Colin Goddard will not become an executive officer of the firm that ends up acquiring OSIP :- )

The only thing I saw in OSI's PR from the 16th was that it had authorized the board to talk to other parties, which is not quite the same thing as actually being in talks with Big Pharmas.

You mean the BoD authorized management to have talks (not the other way around). I don’t draw a distinction between BoD authorization to talk to prospective suitors and actually talking to them. Regards, Dew